Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovis Corporation filings document the formal disclosures of a public medical technology company with Reconstructive and Prevention & Recovery operations. Recent Form 8-K reports cover quarterly and annual results, furnished earnings releases, conference presentation materials and Regulation FD disclosures tied to management presentations.
The filing record also includes proxy materials for annual meeting governance, board and executive compensation matters, executive transition disclosures, and material financing agreements. Enovis filings describe credit facilities, leverage covenants, guarantor arrangements, senior unsecured convertible notes references, financial condition, segment performance and related risk and governance subjects.
Enovis CORP senior vice president and chief human resources officer Patricia A. Lang reported a tax-related share disposition. On this Form 4, the company withheld 497 shares of common stock at $25.47 per share to cover tax obligations tied to restricted stock units, and the footnote clarifies this does not represent a sale by her. After this withholding, she directly owned 54,259 shares of Enovis common stock.
Enovis CORP executive Louis Vogt reported a small tax-related share disposition. On this Form 4, the company withheld 889 shares of common stock at $25.47 per share to cover tax obligations tied to restricted stock units. This withholding is not an open-market sale, and Vogt continues to hold 35,496 shares directly.
Enovis Corp executive reports tax-related share withholding. Group President, P&R Terry D. Ross had 418 shares of Enovis common stock withheld at $25.47 per share to cover tax obligations from restricted stock units. This administrative transaction, described as not representing a sale, leaves Ross holding 35,371 shares directly.
Enovis Corp's Chief Administrative Officer buys additional shares. Oliver Engert purchased 1,000 shares of Enovis common stock in an open-market transaction at a price of $25.50 per share. Following this purchase, he directly owns 43,640 shares of Enovis common stock.
Enovis CORP director Shirley Brady reported a Form 4 transaction involving 1,492 shares of common stock on February 28, 2026. The shares were withheld by the company at $25.47 per share to cover tax obligations tied to the net settlement of restricted stock units and, according to the disclosure, do not represent a sale by Brady. After this tax-withholding event, Brady’s directly held ownership stood at 104,302 shares of Enovis common stock.
Enovis Corp principal accounting officer John Kleckner reported a tax-withholding share disposition related to restricted stock units. The company withheld 315 shares of common stock at $25.47 per share to satisfy tax obligations, which the footnote clarifies does not represent a sale by Kleckner. After this adjustment, he directly holds 11,987 Enovis shares.
Enovis Corp Senior Vice President and Chief Financial Officer Phillip Benjamin (Ben) Berry reported a tax-related share withholding. On February 28, 2026, 720 shares of common stock at $25.47 per share were withheld by the company to cover tax obligations, leaving him with 116,009 directly owned shares. The filing states this withholding does not represent an open-market sale by Berry.
Enovis Corporation files its annual report describing a global medical technology business focused on reconstructive surgery and prevention & recovery devices. The company operates through two segments, sells broadly in the U.S. and Europe, and completed seven bolt‑on acquisitions in 2025 to expand products and distribution.
Enovis highlights extensive risks around acquisitions, leverage, regulation, reimbursement, data privacy and supply chains. It reports significant non‑cash Goodwill impairments of $501.0 million and $540.8 million in 2025 and $645.0 million in 2024 tied to declines in share price and performance at both segments. Non‑affiliate common equity had an aggregate market value of $1.91 billion as of July 4, 2025, and common shares outstanding were 57,245,131 as of February 20, 2026.
Enovis Corporation files its annual report describing a global medical technology business focused on reconstructive surgery and prevention & recovery devices. The company operates through two segments, sells broadly in the U.S. and Europe, and completed seven bolt‑on acquisitions in 2025 to expand products and distribution.
Enovis highlights extensive risks around acquisitions, leverage, regulation, reimbursement, data privacy and supply chains. It reports significant non‑cash Goodwill impairments of $501.0 million and $540.8 million in 2025 and $645.0 million in 2024 tied to declines in share price and performance at both segments. Non‑affiliate common equity had an aggregate market value of $1.91 billion as of July 4, 2025, and common shares outstanding were 57,245,131 as of February 20, 2026.
Enovis Corporation reported fourth-quarter and full-year 2025 results showing steady growth but a large accounting loss driven by goodwill impairment. Fourth-quarter net sales were $575.8 million, up 2.6%, with Reconstructive up 6.9% and Prevention & Recovery roughly flat. Adjusted EBITDA for the quarter was $111.9 million and adjusted diluted EPS was $0.95.
For 2025, net sales reached $2.248 billion, up 6.7% on a reported basis and 5.9% organically. Reconstructive grew 10%, while Prevention & Recovery grew 3.6%. The company recorded a full-year net loss from continuing operations of $1,182 million, or $20.72 per share, largely due to a non-cash goodwill impairment charge of $1,049.8 million. Adjusted EBITDA was $403.0 million and adjusted diluted EPS was $3.30.
Enovis generated $217.3 million in operating cash flow in 2025 and modestly reduced debt. For 2026, it expects revenue of $2.31–2.37 billion with 4–6% organic growth, adjusted EBITDA of $425–435 million, and adjusted EPS of $3.52–3.73.
Enovis Corporation reported fourth-quarter and full-year 2025 results showing steady growth but a large accounting loss driven by goodwill impairment. Fourth-quarter net sales were $575.8 million, up 2.6%, with Reconstructive up 6.9% and Prevention & Recovery roughly flat. Adjusted EBITDA for the quarter was $111.9 million and adjusted diluted EPS was $0.95.
For 2025, net sales reached $2.248 billion, up 6.7% on a reported basis and 5.9% organically. Reconstructive grew 10%, while Prevention & Recovery grew 3.6%. The company recorded a full-year net loss from continuing operations of $1,182 million, or $20.72 per share, largely due to a non-cash goodwill impairment charge of $1,049.8 million. Adjusted EBITDA was $403.0 million and adjusted diluted EPS was $3.30.
Enovis generated $217.3 million in operating cash flow in 2025 and modestly reduced debt. For 2026, it expects revenue of $2.31–2.37 billion with 4–6% organic growth, adjusted EBITDA of $425–435 million, and adjusted EPS of $3.52–3.73.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting a passive ownership stake in Enovis Corp common stock. As of 12/31/2025, Dimensional is deemed to beneficially own 2,781,936 shares, representing 4.9 % of Enovis’s common stock. It reports sole voting power over 2,724,038 shares and sole dispositive power over 2,781,936 shares, with no shared voting or dispositive power.
The shares are actually owned by various funds and accounts it advises (the “Funds”), and Dimensional disclaims beneficial ownership, stating that all securities are owned by the Funds. Dimensional also certifies that the holdings were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Enovis.